Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20061995HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20031176HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20065987HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20061884HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20061827HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20062072HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20038159HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20068307HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20061404HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20016969HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TCGA Plot Options
Drug Information
GeneAHR
DrugBank IDDB12379
Drug NameIndirubin
Target IDBE0003721
UniProt IDP35869
Regulation Typeagonist
PubMed IDs15056799; 25329374
CitationsAdachi J, Mori Y, Matsui S, Matsuda T: Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol Sci. 2004 Jul;80(1):161-9. Epub 2004 Mar 31.@@Perkins A, Phillips JL, Kerkvliet NI, Tanguay RL, Perdew GH, Kolluri SK, Bisson WH: A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain. Biology (Basel). 2014 Oct 17;3(4):645-69. doi: 10.3390/biology3040645.
GroupsInvestigational
Direct ClassificationIndolines
SMILESO=C1NC2=C(C=CC=C2)C1=C1/NC2=C(C=CC=C2)C1=O
Pathways
PharmGKB
ChEMBL